Custirsen

Identification

Generic Name

Custirsen

DrugBank Accession Number

DB05487

Background

Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.

Type

Small Molecule

Groups

Investigational

Structure

Similar Structures

Weight: Average: 7346.14
Monoisotopic: 7340.992685578
Chemical Formula: C₂₃₁H₃₁₂N₇₈O₁₁₉P₂₀S₂₀

Synonyms

Custirsen

External IDs

CC-8490
OGX-011

Pharmacology

Indication

Investigated for use/treatment in brain cancer and breast cancer.

Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:

Machine Learning

Data Science

Drug Discovery

Accelerate your drug discovery research with our fully connected ADMET dataset

Learn more

Contraindications & Blackbox Warnings

With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.

Learn more

Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects

Learn more

Pharmacodynamics

CC-8490, a new anti-cancer compound from Celgene's proprietary class of benzopyrans, being evaluated as a potential therapy for brain cancer. The National Cancer Institute also reports applications in breast cancer related to potential antineoplastic activity. CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.

Mechanism of action

CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.

Preliminary results in studies regarding the mechanism of action in brain cancer suggest that C-8490 surpresses nuclear factor (NF)-KB with its target genes IEX-3, SOD2, IL6, and IL8.

Target	Actions	Organism
UEstrogen receptor alpha	Not Available	Humans
UNuclear factor NF-kappa-B p100 subunit	Not Available	Humans
UNuclear factor NF-kappa-B p105 subunit	Not Available	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Reduce medical errors

and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.

Learn more

Reduce medical errors & improve treatment outcomes with our adverse effects data

Learn more

Toxicity

safe and well tolerated in a Phase I trial in healthy human volunteers.

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Chemical Identifiers

UNII: L26E95NLRK
CAS number: 890056-27-6
InChI Key: RCFZILUHCNXXFY-DEDWCYLFSA-N
InChI: InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1
IUPAC Name: (2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3S,5R)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-4-(2-methoxyethoxy)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy}(sulfanyl)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl [(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl sulfanylphosphonate
SMILES: COCCO[C@@H]1[C@H](O)[C@@H](COP(S)(=O)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@H]5C[C@@H](O[C@@H]5COP(S)(=O)O[C@@H]5[C@@H](COP(S)(=O)O[C@@H]6[C@@H](COP(S)(=O)O[C@@H]7[C@@H](COP(S)(=O)O[C@@H]8[C@@H](CO)O[C@H]([C@@H]8OCCOC)N8C=C(C)C(N)=NC8=O)O[C@H]([C@@H]7OCCOC)N7C=NC8=C7N=CN=C8N)O[C@H]([C@@H]6OCCOC)N6C=NC7=C6N=C(N)NC7=O)O[C@H]([C@@H]5OCCOC)N5C=C(C)C(N)=NC5=O)N5C=NC6=C5N=CN=C6N)N5C=NC6=C5N=C(N)NC6=O)N5C=CC(N)=NC5=O)N5C=NC6=C5N=CN=C6N)N5C=NC6=C5N=C(N)NC6=O)N5C=NC6=C5N=CN=C6N)N5C=NC6=C5N=C(N)NC6=O)N5C=C(C)C(=O)NC5=O)N5C=CC(N)=NC5=O)N5C=C(C)C(=O)NC5=O)N5C=C(C)C(=O)NC5=O)N5C=CC(N)=NC5=O)N5C=NC6=C5N=CN=C6N)O[C@H]([C@@H]4OCCOC)N4C=C(C)C(=O)NC4=O)O[C@H]([C@@H]3OCCOC)N3C=C(C)C(N)=NC3=O)O[C@H]([C@@H]2OCCOC)N2C=NC3=C2N=CN=C3N)O[C@H]1N1C=C(C)C(=O)NC1=O

References

General References

Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA: Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23. [Article]

External Links

PubChem Substance: 347910168
ChemSpider: 34983386
Wikipedia: Custirsen

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Completed	Treatment	Prostate Cancer	2
3	Terminated	Treatment	Castration Resistant Prostate Cancer / Hormone Refractory Prostate Cancer / Hormone-Refractory Prostate Cancer	1
3	Unknown Status	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Prostate Cancer	2
1	Completed	Not Available	Malignancies	1
1	Completed	Treatment	Brain and Central Nervous System Tumors	1
1	Completed	Treatment	Cardiac Conduction and Repolarization	1
1	Completed	Treatment	Glioblastomas / Gliomas, Malignant	1
1, 2	Completed	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-2.2	ChemAxon
pKa (Strongest Acidic)	0.066	ChemAxon
Physiological Charge	-10	ChemAxon
Hydrogen Acceptor Count	127	ChemAxon
Hydrogen Donor Count	47	ChemAxon
Polar Surface Area	2450.68 Å²	ChemAxon
Rotatable Bond Count	154	ChemAxon
Refractivity	1591.03 m³·mol^-1	ChemAxon
Polarizability	653.99 Å³	ChemAxon
Number of Rings	52	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST): Not Available
Spectra: Not Available

Targets

Accelerate your drug discovery research

with our fully connected ADMET & drug target dataset.

Learn more

Accelerate your drug discovery research with our ADMET & drug target dataset

Learn more

Details1. Estrogen receptor alpha

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: Zinc ion binding
Specific Function: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name: ESR1
Uniprot ID: P03372
Uniprot Name: Estrogen receptor
Molecular Weight: 66215.45 Da

Details2. Nuclear factor NF-kappa-B p100 subunit

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name: NFKB2
Uniprot ID: Q00653
Uniprot Name: Nuclear factor NF-kappa-B p100 subunit
Molecular Weight: 96748.355 Da

Details3. Nuclear factor NF-kappa-B p105 subunit

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name: NFKB1
Uniprot ID: P19838
Uniprot Name: Nuclear factor NF-kappa-B p105 subunit
Molecular Weight: 105355.175 Da

Drug created on November 18, 2007 18:25 / Updated on February 21, 2021 18:51

Custirsen

Identification

Structure for Custirsen (DB05487)

Pharmacology

Interactions

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets